Goldman Sachs Group Inc Sigilon Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$0.34 - $1.38 $3,976 - $16,140	11,696 Added 69.2%	28,598 $26,000
Q1 2023 May 11, 2023	BUY	$0.34 - $1.38 $3,976 - $16,140	11,696 Added 69.2%	28,598 $26,000
Q4 2022 May 14, 2024	SELL	$0.29 - $0.69 $94 - $224	-325 Reduced 1.89%	16,902 $5,000
Q4 2022 Feb 13, 2023	SELL	$0.29 - $0.69 $94 - $224	-325 Reduced 1.89%	16,902 $5,000
Q3 2022 May 14, 2024	BUY	$0.48 - $0.86 $94 - $169	197 Added 1.16%	17,227 $9,000
Q3 2022 Nov 10, 2022	BUY	$0.48 - $0.86 $94 - $169	197 Added 1.16%	17,227 $0
Q2 2022 May 14, 2024	BUY	$0.74 - $1.64 $12,602 - $27,929	17,030 New	17,030 $14,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $1.64 $1,386 - $3,071	1,873 Added 12.36%	17,030 $14,000
Q1 2022 May 16, 2022	SELL	$1.24 - $3.03 $50,057 - $122,318	-40,369 Reduced 72.7%	15,157 $22,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $19,778 - $46,992	7,666 Added 16.02%	55,526 $154,000
Q3 2021 Nov 10, 2021	BUY	$4.42 - $10.61 $211,541 - $507,794	47,860 New	47,860 $270,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.